Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib in HER2-positive advanced solid tumors
NCT04179656Phase 2Unknown
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Dec 2019
- Primary completion
- Dec 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in solid tumor, sponsored by The Second Hospital of Tianjin Medical University. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04179656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04179656.